As of close of business last night, Avadel Pharmaceuticals plc ADR’s stock clocked out at $12.78, up 1.83% from its previous closing price of $12.55. In other words, the price has increased by $+0.23 from its previous closing price. On the day, 1613553 shares were traded.
Ratios:
To gain a deeper understanding of AVDL’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.09 and its Current Ratio is at 3.19. In the meantime, Its Debt-to-Equity ratio is 0.50 whereas as Long-Term Debt/Eq ratio is at 0.30.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, UBS on February 06, 2024, initiated with a Buy rating and assigned the stock a target price of $21.
On November 30, 2022, Jefferies Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $6.50 to $11.
Jefferies Downgraded its Buy to Hold on August 10, 2022, whereas the target price for the stock was revised from $6 to $8.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 16 when MCHUGH THOMAS S bought 2,000 shares for $14.50 per share. The transaction valued at 29,000 led to the insider holds 80,500 shares of the business.
McCamish Mark Anthony sold 75,000 shares of AVDL for $1,089,750 on Dec 28. The Director now owns 67,025 shares after completing the transaction at $14.53 per share. On Aug 14, another insider, MCHUGH THOMAS S, who serves as the Chief Financial Officer of the company, bought 2,000 shares for $14.45 each. As a result, the insider paid 28,900 and bolstered with 78,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AVDL now has a Market Capitalization of 1.13B and an Enterprise Value of 997.96M. For the stock, the TTM Price-to-Sale (P/S) ratio is 134.26 while its Price-to-Book (P/B) ratio in mrq is 10.98. Its current Enterprise Value per Revenue stands at 117.27 whereas that against EBITDA is -6.83.
Stock Price History:
Over the past 52 weeks, AVDL has reached a high of $17.24, while it has fallen to a 52-week low of $8.00. The 50-Day Moving Average of the stock is 14.25, while the 200-Day Moving Average is calculated to be 13.24.
Shares Statistics:
It appears that AVDL traded 1.01M shares on average per day over the past three months and 1.13M shares per day over the past ten days. A total of 89.40M shares are outstanding, with a floating share count of 74.49M. Insiders hold about 16.67% of the company’s shares, while institutions hold 56.43% stake in the company. Shares short for AVDL as of Feb 15, 2024 were 8.86M with a Short Ratio of 8.76, compared to 6.52M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 9.87% and a Short% of Float of 9.95%.
Earnings Estimates
As of right now, 8 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.29 for the current quarter, with a high estimate of -$0.23 and a low estimate of -$0.34, while EPS last year was -$0.46. The consensus estimate for the next quarter is -$0.25, with high estimates of -$0.21 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$0.64 and -$2.02 for the fiscal current year, implying an average EPS of -$1.83. EPS for the following year is -$0.45, with 8 analysts recommending between -$0.2 and -$0.56.
Revenue Estimates
Based on 8 analysts’ estimates, the company’s revenue will be $152.83M in the next fiscal year. The high estimate is $176.64M and the low estimate is $122.6M. The average revenue growth estimate for next year is up 472.60% from the average revenue estimate for this year.
